Chief Executive Officer and Board Director

Arthur T. Sands, M.D., Ph.D., serves as the Chief Executive Officer at Nurix and is a member of the company’s board of directors. Prior to joining Nurix, Dr. Sands co-founded Lexicon Pharmaceuticals and served as President, Chief Executive Officer and a Director since 1995. At Lexicon, Dr. Sands pioneered the development of large-scale gene knockout technology for use in drug discovery and guided the evolution of Lexicon from a research-stage company to a drug development company, catalyzed by numerous alliances with Bristol Myers Squibb, Takeda and Genentech, and generating more than $450 million in revenue. Dr. Sands serves as Adjunct Professor in the Department of Human and Molecular Genetics at Baylor College of Medicine. He has also published many scientific and medical articles and is an inventor on numerous patents related to the discovery of human genes and their use in the development of new therapies. Dr. Sands holds an M.D. and a Ph.D. from Baylor College of Medicine and a B.A. in economics and political science from Yale University.

Chief Business Officer

Pierre Beaurang, Ph.D., serves as Chief Business Officer at Nurix. Prior to joining Nurix, Dr. Beaurang was part of the founding team of Five Prime Therapeutics where he contributed to the conceptualization, creation and implementation of the company plan. Dr. Beaurang held roles of increasing responsibility and negotiated a number of major collaborations with global pharmaceutical firms, including with GlaxoSmithKline, UCB and Bristol Myers Squibb, helping secure an aggregate $270 million in near term revenues and more than $2.4 billion in potential milestone payments. Dr. Beaurang holds a Ph.D. in molecular and cell biology from the University of California, Berkeley and conducted postdoctoral research at the University of California, San Francisco. He holds a B.A. and a M.A. in biology and biotechnology, respectively, from Boston University.

TUN_4734-rectangle 2.jpg

Chief Development Officer

Nancy Pryer, Ph.D. is Chief Development Officer at Nurix. She is a translational sciences leader with extensive experience leading the discovery and advancement of novel therapeutic candidates to exploratory clinical development. Prior to joining Nurix, Dr. Pryer served as Vice President of Translational Sciences at BioMarin Pharmaceutical where she led the company’s significant efforts in biomarker discovery, bioanalytical sciences, immunogenicity assessment and clinical pharmacology. Prior to joining BioMarin, Dr. Pryer held leadership roles in oncology drug discovery and translational development at Novartis Institutes for Biomedical Research, Raven, SUGEN and Onyx Pharmaceuticals.  Dr. Pryer received her Ph.D. in Biology from the University of North Carolina, Chapel Hill, and completed post-doctoral work at the University of California, Berkeley.  She holds a B.S. in Zoology from the University of California, Davis.

Vice President, Operations & Corporate Counsel

Howard Simon is Vice President, Operations & Corporate Counsel at Nurix. Prior to joining Nurix, Mr. Simon was Chief Operating Officer & General Counsel at DNA2.0, Inc., an industry leader in gene synthesis and protein engineering, where he managed general operations, human resources and legal matters. Previously, Mr. Simon also served as Senior Vice President, Human Resources & Corporate Services, Associate General Counsel & Chief Compliance Officer at InterMune, Inc. (now Roche) where he was part of the team that developed the world’s first on-label therapy for idiopathic pulmonary fibrosis. Mr. Simon holds a J.D. from Boalt Hall (UC Berkeley), an MBA from Babson College, an M.A. from the Graduate Theological Union of Berkeley and an undergraduate degree from UC Berkeley. Mr. Simon is a recognized expert in biosecurity and serves as an officer and director of the not-for-profit International Gene Synthesis Consortium, an organization devoted to advancing global biosecurity in the synthetic biology industry.

Senior Vice President, Finance

Hans van Houte is Vice President, Finance at Nurix. Prior to joining, Mr. van Houte served as acting CFO for multiple new biotechnology companies formed with investments totaling over $150 million from Third Rock Ventures and The Column Group. Mr. van Houte previously held senior financial roles in biotechnology companies including Vice President, Finance and Administration at Trubion Pharmaceuticals where he was part of the team that took Trubion public in October 2006. Prior to Trubion Mr. van Houte was the Controller, Treasurer and Principal Accounting Officer at Vertex Pharmaceuticals, where he helped build the financial and accounting organization post-IPO to support growth from a $100 million to a multibillion market capitalization. Mr. van Houte received a B.S. in Business Management from Babson College.